Filing Details
- Accession Number:
- 0000899243-18-028003
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-11-02 16:05:22
- Reporting Period:
- 2018-11-01
- Accepted Time:
- 2018-11-02 16:05:22
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1160308 | Savara Inc | SVRA | Pharmaceutical Preparations (2834) | 841318182 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1408498 | L David Lowrance | 6836 Bee Cave Road, Building Iii Suite 200 Austin TX 78746 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2018-11-01 | 18,480 | $9.22 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 19, 2018.
- The price is a weighted average sale price. The sale prices ranged from $9.02 to $9.34. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.